Liver function testing in patients on HMG-CoA reductase inhibitors

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 4, 2003, Pages 307-313

  Andrade, Susan E ^a   Donahue, James G ^b   Chan, K Arnold ^b,c   Watson, Douglas J ^d   Platt, Richard ^b,e  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

HMG CoA reductase inhibitors; Liver function tests

Indexed keywords

ANTILIPEMIC AGENT; DICLOFENAC; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TROGLITAZONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG LABELING; DRUG USE; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH MAINTENANCE ORGANIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PRIORITY JOURNAL; RANDOMIZATION; RETROSPECTIVE STUDY; SAMPLE;

AGED; DRUG LABELING; FEMALE; HEPATITIS, TOXIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037832551     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.832     Document Type: Article

References (15)

1. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-213.
2. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43-49.
3. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156: 2085-2092.
4. Shepherd J, Cobbee SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
6. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of crosstoxicity with simvastatin. Lancet 1999; 353: 1763-1764.
7. Mantell G, Burke T, Staggers J. Extended clinical safety profile of lovastatin. Am J Cardiol 1990; 66: 11B-15B.
8. Ballare M, Campanini M, Airoldi G, et al. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors. Minerva Gastroenterol Dietol 1992; 38: 41-44.
9. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24-32.
10. Andrade SE, Walker AM, Hollenberg NK, et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-1131.
11. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. John Wiley: New York, 1980.
12. Walker AM, Bortnichak EA, Lanza L, Yood RA. The infrequency of liver function testing in patients using nonsteroidal anti-inflammatory drugs. Arch Fam Med 1995; 4: 24-29.
13. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605-610.
14. Swislocki ALM, Lin K, Cogburn D, Fann KY, Khuu DT, Noth RH. Postmarketing analysis of lovastatin use in the VA Northern California system of clinics: a retrospective, computer-based study. Am J Man Care 1997; 3: 1537-1545.
15. Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286: 831-833.